1	Immunohistochemical Profiling of Histone Modification Biomarkers Identifies									
2	Subtype-Specific Epigenetic Signatures and Potential Drug Targets in Breast Cancer									
3	Zirong Huo ¹ , Sitong Zhang ¹ , Guodong Su ¹ , Yu Cai ¹ , Rui Chen ¹ , Mengju Jiang ¹ , Dongyan									
4	Yang ¹ , Shengchao Zhang ¹ , Yuyan Xiong ¹ , Xi Zhang ^{1,2} *									
5										
6	1 School of Life Science, Northwest University, Xi'an, Shaanxi 710069, China									
7	2 School of Professional Studies, Northwestern University, Evanston, IL 60201, US									
8	* Corresponding author									
9										
10	Zirong Huo: <u>hzr1661864339@163.com</u>									
11	Sitong Zhang: <u>zstongoo@163.com</u>									
12	Guodong Su: <u>1938824365@qq.com</u>									
13	Yu Cai: <u>caiyu1316@163.com</u>									
14	Rui Chen: <u>yourangle@126.com</u>									
15	Mengju Jiang: <u>1441564131@qq.com</u>									
16	Dongyan Yang: 202322544@stumail.nwu.edu.cn									
17	Shengchao Zhang: <u>zhangshengchao0601@163.com</u>									
18	Yuyan Xiong: <u>yuyan.xiong@nwu.edu.cn</u>									
19	Xi Zhang: <u>xzhang19@nwu.edu.cn</u>									

21 Abstract

Background: Breast cancer (BC) subtypes exhibit distinct epigenetic landscapes, with 22 triple-negative breast cancer (TNBC) lacking effective targeted therapies. This study 23 investigates histone biomarkers and therapeutic vulnerabilities across BC subtypes. 24 **Methods:** Immunohistochemical profiling of >20 histone biomarkers, including histone 25 26 modifications, modifiers and oncohistone mutations was conducted on a discovery cohort and a validation cohort of BC tissues, healthy controls and cell line models. 27 28 Transcriptomic and cell growth analyses were conducted to evaluate the effects of the 29 small-molecule G9a inhibitor in diverse BC models. Results: Key histone biomarkers, 30 including H3K9me2, H3K36me2, and H3K79me, were differentially expressed across 31 BC subtypes. H3K9me2 emerged as an independent predictor for distinguishing TNBC 32 from other less aggressive BC subtypes, with elevated expression correlating with higher 33 tumor grade and stage. G9a inhibition impaired cell proliferation and modulated 34 epithelial-mesenchymal transition pathways, with the strongest impact in basal-like TNBC. Disruption of oncogene and tumor suppressor regulation (e.g., TP53, SATB1) 35 was observed in TNBC. Conclusion: This study highlights G9a's context-dependent roles 36 37 in BC, supporting its potential as a therapeutic target. Findings provide a foundation for subtype-specific epigenetic therapies to improve outcomes in aggressive BC subtypes. 38

39 Keyword

40 Histone Modification, Immunohistochemical Profiling, Triple-negative Breast Cancer,41 G9a Inhibitor

42

43 Clinical Perspective

44	•	This study was undertaken to explore the epigenetic landscape of breast cancer
45		subtypes, focusing on histone modifications and their therapeutic potential,
46		particularly through targeting G9a, a histone methyltransferase.
47	•	The study identified subtype-specific histone biomarkers, with H3K9me2
48		emerging as a key marker distinguishing TNBC from other less aggressive
49		subtypes. G9a inhibition demonstrated robust anti-cancer effects, including cell
50		proliferation impairment and disruption of oncogenic pathways, particularly in
51		TNBC models.
52	•	These findings provide compelling evidence for the development of subtype-
53		specific epigenetic therapies targeting G9a and similar regulators, highlighting
54		their potential to reshape the treatment landscape for TNBC and improve patient
55		outcomes.

58 Introduction

59 Histones, as the core components of chromatin, undergo chemical modifications that 60 regulate gene expression and are intimately linked to cancer development[1]. Histone 61 modifications such as methylation and acetylation act as pivotal regulators of gene 62 activity, influencing transcriptional regulation and tumor progression depending on their 63 type and genomic context[2, 3]. For instance, H3K4me2 is a mark of active transcription, typically found at promoters of genes primed for expression. Conversely, H3K9me2 is 64 associated with transcriptional repression and heterochromatin formation, silencing genes 65 that may drive tumorigenesis. However, the loss of H3K9me2 can paradoxically activate 66 oncogenes, contributing to cancer progression. 67

BC is a highly heterogeneous disease, classified into distinct molecular subtypes based on 68 the expression of classic biomarkers such as Estrogen Receptor (ER), Progesterone 69 70 Receptors (PR) and Human Epidermal Growth Factor Receptor 2 (HER2)[4]. Among these, TNBC poses the greatest clinical challenge due to its aggressive nature and the 71 72 absence of well-defined therapeutic targets. Bridging the treatment gaps in TNBC 73 necessitates innovative approaches, particularly those focusing on its unique molecular 74 and epigenetic characteristics [5]. Aberrations in histone modifications in cancer can vary 75 significantly, even within the same cancer type. Research has demonstrated that different 76 molecular subtypes of BC (e.g., luminal A and TNBC) exhibit distinct patterns of histone modifications, reflecting subtype-specific epigenetic landscapes[6]. Although evidence 77 from cell line studies have highlighted that TNBC is the molecular subtype that most 78 79 closely associated with distinct histone modification patterns [7, 8], research focusing on 80 human tissue remains limited. This gap underscores the need for studies using patient-

81 derived samples to validate findings from in vitro models and to explore the clinical
82 relevance of these epigenetic alterations in tumor progression.

The unique histone modification patterns of TNBC, once fully characterized, may 83 84 distinguish it from subtypes like luminal A and HER2-enriched breast cancers, highlighting new possibilities for subtype-specific therapies[9]. Current epigenetic 85 86 treatments, including DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors, show clinical promise[10]. Histone methyltransferase (HMT) inhibitors 87 correspond to the third generation of epigenetic drugs capable of writing or deleting 88 89 epigenetic information[11, 12]. EZH2 inhibitor, targeting H3K27me3, is the first and only 90 HMT inhibitor that approved by FDA in 2020 for the treatment of certain cancers[13, 14]. 91 Emerging targets like H3K79me1/2/3 (DOT1L inhibitors) and H3K9me2 (G9a inhibitors) are showing potential in preclinical studies of breast cancer[15-17]. 92

93 In this study, the global expression of histone modifications, histone modifiers, and oncohistone mutations was characterized in BC tissues using immunohistochemical (IHC) 94 staining. Expression patterns were validated across two independent cohorts and 95 96 compared to those in healthy tissue samples and BC cell lines. Subtype-specific histone modifications were identified, with several significant ones showing strong associations 97 98 with the TNBC subtype, tumor grade, and stage. Treatment with a small-molecule 99 epigenetic inhibitor significantly impaired cell growth in both estrogen receptor-positive 100 and -negative cell lines. Transcriptomic and pathway analyses further confirmed distinct 101 responses between the two cell line types. Together, these findings highlight specific 102 histone modifications as critical markers and drivers of advanced or accelerated breast 103 cancer progression and establish histone modifiers as promising therapeutic targets in BC.

104 Method

105 Study Design

To identify and evaluate the potential of 21 pathological biomarkers in breast cancer, this 106 study used tissue microarray technology, allowing for high-throughput molecular analysis 107 of 196 tissue samples from a discovery cohort of 98 breast cancer patients (Fig. 1). The 108 IHC profiling results of TNBC were then validated by additional 20 tissue blocks from a 109 validation cohort of 20 TNBC patients. Eligible participants of both cohorts were women 110 111 aged 35-70 years with a first primary diagnosis of breast cancer (Table 1). The distributions of clinical characteristics and traditional pathological biomarker results are 112 shown for both the discovery and validation cohorts, as provided by the commercial 113 vendors of BC tissues. Based on IHC assessments of ER, PR, HER2, and Ki-67, breast 114 cancer samples in this study were classified into 79 luminal A cases, 53 luminal B cases, 115 23 HER2-enriched cases, and 41 TNBC cases in the discovery cohort, as well as 20 116 TNBC cases in the validation cohort. Histone biomarker signatures identified from tissue 117 samples were subsequently evaluated in BC cell lines. To explore their functional 118 119 relevance, the selected HMT inhibitor, G9a inhibitor UNC0642, was applied to assess its effects on cell proliferation, impacted gene expression and signaling pathways. All study 120 121 procedures were approved by the Institutional Ethics Committee and the Institutional 122 Review Board of Northwest University (approval number: 200,402,001).

123 **Tissue Specimens**

124

We collected 216 tissue samples from commercial sources for this study. A high-density breast cancer tissue microarray (chip number F1961101 B06-F1961101 B25) was purchased from Xi'an Bioaitech Co., Ltd. Each chip included two 1-mm tissue cores from 98 patients with various molecular subtypes, forming a discovery cohort of 196 samples. A validation cohort was established using 20 TNBC tissue slides procured from Shanghai Xinchao Co., Ltd. (sample codes listed in Table S4). Clinical characteristics and biomarker data were available for all tissue samples (Table 1).

132 Cell Culture

Three breast cancer cell lines—MCF-7 (luminal A), MDA-MB-231 (claudin-low TNBC), 133 and MDA-MB-468 (basal-like TNBC)—and two T-lymphocytic leukemia cell lines 134 (HPB-ALL and LOUCY) were used in this study. Origin and catalogue number of cell 135 136 lines are listed in Table S4. Three BC cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM). HPB-ALL and LOUCY cells were cultured in RPMI-1640. In 137 both media, 10% fetal bovine serum and 1% penicillin/streptomycin were added. The 138 139 above cells were grown in a humidified 5% CO₂ incubator at 37°C. For estrogen 140 treatment, cells were starved in phenol red-free DMEM supplemented with 10% charcoal-stripped FBS for 2 days, and 73.4 mM estrogen were added to the medium (3 141 142 and 6 h for gene expression studies, and 6 h for immunocytochemical (ICC) experiments) 143 before the cells were collected. The detailed list of reagents and kits used in the method can be found in Table S4. 144

145 IHC and ICC

IHC analysis was performed using the streptavidin-biotin-peroxidase complex method to 146 evaluate 20 histone biomarks (including H3) of interest. Tissue chips and slides were 147 processed by deparaffinization, antigen retrieval, blocking with goat serum, and 148 incubation with primary antibodies overnight at 4°C. Secondary antibodies and DAB 149 were used for detection, followed by counterstaining and mounting. Anti-H3 served as a 150 151 control. Details of antibodies, reagents and kits are provided in Table S4. ICC was performed using the same principles as IHC. Cells were fixed in 4% paraformaldehyde, 152 permeabilized with 0.25% Triton X-100, and blocked with 10% goat serum. Primary 153 antibodies were incubated overnight, followed by secondary antibody incubation and 154 DAB detection. 155

156 Cell Viability and Proliferation Assay

157 Cell viability was assessed using the Cell Counting Kit-8 (CCK-8). Cells were seeded in 158 96-well plates (5×10^3 /well), treated with UNC0642 or DMSO (Control), and incubated. 159 After treatment, 10 µL CCK-8 solution was added, and OD450 was measured. For 160 proliferation assays, cells were treated with 2 µM UNC0642 or DMSO and analyzed over 161 six days using the same method. The detailed list of reagents and kits used in the method 162 can be found in Table S4.

163 Western Blotting

Proteins form BC cells, which were treated with 2 µM UNC0642 or DMSO for 48 h and
were extracted using RIPA buffer, quantified using the BCA assay, and separated by SDSPAGE. After transfer to PVDF membranes, blots were incubated with primary and

secondary antibodies. Signals were detected using enhanced chemiluminescence, with H3as a loading control. Antibodies, reagents and kits details are listed in Table S4.

169 RNA isolation and Sequencing

Total RNA from BC cells collected after 4 days of treatment with 2 µM UNC0642 or 170 171 DMSO was extracted using Trizol and assessed for purity and integrity. RNAseq libraries were prepared using the TruSeq RNA Sample Prep Kit and sequenced on an Illumina 172 NovaSeq 6000 platform. Clean reads were analyzed using STAR aligner and DESeq2 to 173 174 identify differentially expressed genes (DEGs). Genes in breast cancer cell lines that displayed at least one-fold difference in gene expression between comparison groups 175 176 (fold change > 1 or < -1, FDR p < 0.05) were considered significant DEGs and carried 177 forward in the analysis. Pathway and gene ontology (GO) enrichment analysis was performed via an integrated platform KOBAS 3.0 and GSEA using MSigDB gene sets 178 within selected collections H, C2, C4, C6. Bioinformatics analysis was performed and 179 visualized using R version 3.6.1 or Python version 3.7.9. The detailed list of reagents and 180 kits used in the method can be found in Table S4. 181

182 **Real-time quantitative PCR (RT-qPCR)**

183 Real-time quantitative PCR was performed using Bio-Rad real-time PCR systems. Total 184 RNA (1 μ g) was reverse transcribed into cDNA using the Hifair III 1st Strand cDNA 185 Synthesis SuperMix for qPCR. mRNA expression levels were quantified using Hieff® 186 qPCR SYBR Green Master Mix, with relative expression calculated by the 2^{- $\Delta\Delta$ Ct} method. 187 Each sample was tested in triplicate, and primers, reagents and kits are listed in Table S4.

188 IHC Evaluation and Cutoff Determination

Histone expression was quantified using integrated optical density (IOD) values from 189 Image J (Media Cybernetics Inc., Rockville, MD, USA) analysis[18]. Receiver operating 190 191 characteristic (ROC) curve analysis was used to determine cutoff scores for each histone, distinguishing high and low expression[19]. Clinical features, including age, grade, T 192 193 stage, N stage, tumor stage, and receptor status, were classified for analysis. For each 194 histone biomarker, the point of maximum sensitivity and specificity was selected based on the area under the curve. Samples were classified as low expression if their integrated 195 196 optical density was below the cutoff and high expression if equal to or above the cutoff. 197 Clinical features used for stratification in ROC analysis included: Age (\geq 50 vs. <50 years), Tumor Grade (Grade 2 vs. 2-3/3), T stage (T1/T2 vs. T3/T4), N stage (N0 vs. 198 199 N1/N2), Tumor Stage (Stage I vs. Stage II/III), Receptor Status (ER/PR/HER2 negative vs. positive), Ki-67 Index (<14% vs. >14%). These cutoff values provided a basis for 200 201 categorizing histone expression and analyzing its association with breast cancer subtypes 202 and clinical outcomes.

203 Statistical Analysis

Statistical analyses were conducted using SPSS (v13.0) and GraphPad Prism 9. T-tests,
chi-square tests, and logistic regression were used to analyze data.

206 **Results**

207 Pathological Scoring Identified Key Histone Biomarkers across BC Molecular 208 Subtypes

To characterize the global expression of histone biomarkers in tissue samples, IHCstaining was initially performed on two cohorts of BC patients. The analysis included 12

histone modifications, 7 histone modifiers, 2 oncohistone mutations, and histone H3 as a 211 212 control signal (Fig. 2A). The histone modifications and modifiers selected in this study 213 are recognized for their roles in driving dysregulated gene expression patterns in breast cancer (Fig. 2A) and will henceforth be termed histone biomarkers. The first cohort, 214 referred to as the discovery cohort, comprised 196 tissue spots (Fig. 2B). These were 215 216 derived from 98 patients (Table 1), with duplicate spots collected per patient. Each IHC staining spot was scored by combining the area and density of the dyed region assessed 217 218 by Image J. The samples were then categorized into two classes: High-IHC score and 219 Low-IHC score (Fig. 2C).

220 The molecular subtypes of BC tissues (luminal A, luminal B, HER2-enriched, and TNBC) 221 in the discovery cohort were determined by analyzing IHC staining patterns for ER, PR, HER2, and Ki-67 (Fig. 3A). Heatmap of high-IHC % suggests that high-IHC scores are 222 223 not uniformly distributed among the molecular subgroups (Figs. 3B & 3C). Statistical 224 analyses were conducted to assess the significance of the distribution of histone biomarker levels. Initially, chi-square tests were performed to assess the difference in the 225 226 distribution of histone biomarkers across sample subgroups defined by clinical 227 characteristics as described in Table 1. As presented in Table 2 and Fig 3B, six histone biomarkers (H3K4me2, H3K9me2, H3K36me2, LSD1, NSD1, and DNMT1) showed 228 229 significant differences across the four molecular subtypes. H3K9me2, H3K36me2, H3K79me (me1/2/3) and two acetylation markers (H3K18ac and H4K16ac) exhibited 230 231 significant differences in TNBC compared to other molecular subtypes.

Logistic regression analysis was then conducted to explore the relationship between IHC
scores (High-IHC vs. Low-IHC) and histone biomarkers (Table 3), excluding the

oncohistone mutations that were not detectable in any of the tissue samples (Fig. S1). 234 235 Univariate regression was performed to evaluate the association of each histone 236 biomarker with the IHC score individually. Histone biomarkers with p-values below 0.05 in the univariate analysis were subsequently included in the multivariate regression 237 model. The analysis highlighted H3K9me2, H3K36me2, and H3K79me (me1/2/3) as 238 239 independent predictors of altered IHC scores in TNBC compared to other molecular subtypes. G9a, the only histone modifier that exhibited significant differences in TNBC, 240 241 was determined to be a dependent predictor. Furthermore, H3K9me2 and H3K36me2, along with H3K4me2 and others, were also identified as independent predictors for the 242 243 luminal A and luminal B subtypes.

244 Key Histone Biomarkers Serve as Indicators of Advanced Tumorigenesis in BC

Next, we aimed to evaluate the expression levels of selected histone biomarkers in 245 adjacent healthy breast tissue compared to breast cancer tissue. Due to material 246 limitations, the analysis focused on histone H3, three specific histone modifications 247 (H3K4me2, H3K9me2, and H3K9ac), and two corresponding modifiers (G9a and LSD1). 248 249 Representative IHC images of luminal A breast cancer and TNBC are displayed side by side (Fig. 4A). IHC images of two additional independent TNBC predictors, H3K36me2 250 251 and H3K79me, are presented alongside LSD1. Histone biomarkers and corresponding 252 modifiers exhibited clustered expression patterns, as demonstrated in heatmap analyses (Fig. 3B). Interestingly, histone biomarkers commonly associated with transcriptional 253 repression (H3K9me2, G9a and LSD1) were more highly expressed in TNBC compared 254 255 to luminal A and were also elevated in breast cancer tissue compared to healthy tissue. In 256 contrast, the expression of biomarkers associated with transcriptional activation

257 (H3K4me2 and H3K9ac) followed a decreasing trend, with the lowest levels observed in

258 TNBC, intermediate levels in luminal A, and the highest levels in healthy tissue.

259 The MCF-7 cell line treated with estrogen is a well-established luminal A breast cancer 260 model for studying estrogen-driven regulation. A positive transcriptional response to 261 estrogen is central to the biology of ER-positive breast cancer and serves as a hallmark of 262 disease progression and treatment response (Fig. S2). To further explore the identified key histone biomarkers, their global expression was assessed via ICC staining in 263 estrogen-treated MCF-7 cells. Notably, the histone biomarkers H3K9me2 and G9a, out of 264 the five markers characterized above in tissue samples, showed increased expression in 265 266 estrogen-treated MCF-7 cells compared to estrogen-deprived cells (Fig. 4B). Additionally, several other methylation and acetylation markers exhibited altered expression in this 267 cellular model (Fig. S3), indicating a complex epigenetic landscape in ER-responsive 268 regulation in breast cancer. These findings reinforce the association of H3K9me2 and 269 270 G9a with advanced tumorigenesis in breast cancer and underscore their roles in 271 promoting estrogen-dependent tumor growth and progression.

272 Validation of Altered Global Histone Modification in TNBC Tissue

As the role of G9a and H3K9me2 in ER-positive breast cancer is better understood, the focus of this study shifted toward further exploring the significance of key histone biomarkers in TNBC. To validate these findings, a second breast cancer cohort was established, comprising 20 tissue slides from 20 TNBC cases. The clinical characteristics of the validation cohort are summarized, with no significant differences observed between the discovery and validation cohorts (Table 1). Each tissue sample was stained

279 for 4 histone biomarkers, and the IHC results were scored and classified into IHC-high 280 and IHC-low categories as described previously (Table 4). The IHC-high percentages of 281 TNBC-independent predictors (H3K9me2, H3K36me2, H3K79me) and modifier G9a in the validation cohort are provided in Table 4, alongside corresponding metrics for TNBC 282 and luminal A cases in the discovery cohort. Significant differences (p<0.05) were 283 284 observed in the IHC-high% of all three independent predictors when comparing the at least one TNBC cohort to luminal A, but no significant difference was found between 285 286 validation TNBC and discovery TNBC. This finding confirmed the agreement on the 287 significance of key histone biomarkers between two TNBC cohorts and further 288 highlighted the distinction between TNBC and luminal A, in addition to the results described above comparing TNBC with all non-TNBC subtypes. 289

Among the three histone biomarkers validated in this study, H3K9me2 was selected for 290 291 further analysis. One reason for this selection is that while the roles of G9a and 292 H3K9me2 have been extensively studied in ER-positive breast cancer, their involvement in TNBC remains largely unexplored, despite strong prior associations. Another reason is 293 that global H3K9me2 signals were significantly linked to tumor grade, as well as T and N 294 295 stages (Table 2, Fig 5A). Notably, a gradual increase in H3K9me2 level (IHC-high%) was observed with higher tumor grade or stage (T4 > T3 > T2) (Fig 5B). This pattern 296 suggests that H3K9me2 may be associated with more aggressive or advanced breast 297 cancer status or subtypes, such as TNBC, which are characterized by higher proliferation 298 299 rates and poorer clinical outcomes.

G9a Inhibition Disrupts Proliferation and Signaling Pathways in Breast Cancer Cell Lines

302 UNC0642, a novel small-molecule inhibitor targeting the catalytic activity of G9a, was evaluated in MCF-7 (luminal A), MDA-MB-231 (claudin-low TNBC), and MDA-MB-303 304 468 (basal-like TNBC) cell lines. Cell viability assays were performed to optimize the dose and treatment duration (Fig. 6A). Finally, non-cytotoxic concentrations of UNC0642 305 $(2 \mu M)$ were applied in all subsequent experiments. This inhibitor demonstrated 306 307 significant efficacy in reducing H3K9me2 levels in all three cell lines, as confirmed by both pathological staining and Western blotting analysis (Figs. 6B & 6C). Other histone 308 309 modifications, such as H3K4me2, or alternative modifications at the same residue, such 310 as H3K9ac, remained unaffected, indicating the high specificity of UNC0642. Interestingly, G9a protein levels were also reduced in basal-like TNBC cells, which 311 exhibited a more pronounced decrease in H3K9me2 compared to claudin-low TNBC 312 cells. UNC0642 treatment resulted in marked growth inhibition across all tested cell lines, 313 314 with the most significant effects observed in basal-like TNBC cells, followed by claudin-315 low TNBC cells, and moderate effects in luminal A cells (Fig. 6D).

In line with the expected effects of losing the repressive histone mark H3K9me2, the 316 number of up-regulated DEGs was 5-fold higher than down-regulated DEGs in two ER-317 318 negative cell lines (Fig. 7A, Fig S4A, Table S1). In contrast, ER-positive MCF-7 cells showed a balanced number of up- and down-regulated DEGs, aligning with prior reports 319 320 that G9a mediate a direct methylation on ER that was functionally linked to breast cancer progression [17, 20] (Fig. 7A, Fig S4A, Table S1). To further understand the impact of 321 UNC0642, we performed pathway, GO, and GSEA analyses to evaluate gene group and 322 pathway-level responses. The results revealed both shared and distinct transcriptional 323 responses across the three cell lines, highlighting subtype-specific mechanisms of action 324

for the inhibitor (Fig. 7B, Fig S4A). In MCF-7 cells, estrogen-responsive pathways and 325 gene sets were exclusively down-regulated, supporting previous findings that G9a acts as 326 327 an ERa coactivator [17] (Fig. 7C, Fig. S4B, Tables S2 & S3). Interestingly, G9a inhibition in MDA-MB-231 cells led to a transcriptional response characterized by up-328 regulation of oncogenes such as SREBF and down-regulation of tumor suppressor genes 329 330 such as TP53, STAT3 and SATB1 (Fig. 7D, Tables S2 & S3). Cell proliferation pathways and extracellular matrix (ECM)-associated gene sets are consistently down-regulated in 331 332 both ER-negative and ER-positive cells, emphasizing the shared growth-suppressive 333 effects of G9a inhibition and underscoring its significant therapeutic potential across these breast cancer subtypes (Fig. 7E). 334

335 Discussion

Significant efforts have been dedicated to systematically profiling histone modifications 336 and the enzymes that regulate them in ER-positive BC[21]. These studies have been 337 pivotal in driving the development and clinical application of the first two generations of 338 epigenetic drugs, such as DNMT inhibitors and HDAC inhibitors, with the third 339 340 generation targeting HMTs now emerging. However, similar insights into histone modification landscapes and their therapeutic potential remain scarce for TNBC, a 341 342 subtype known for its aggressive and invasive nature. A greater challenge in developing 343 epigenetic drugs is their specificity, which requires emphasis on identifying biomarkers capable of predicting how individual patients will respond to these therapies. This study 344 aimed to address this critical knowledge gap by unveiling key histone biomarker patterns 345 346 in BC with a specific focus on TNBC. Among the >20 histone biomarkers evaluated, our findings reveal significant alterations in 4 specific histone modification/modifier pairs 347

(H3K4me2/LSD1, H3K9me2/G9a, H3K36me2/NSD1, DNMT1) across the four major
BC molecular subtypes. These findings align with the established evidence supporting
epigenetic therapy in driving ER-positive breast cancer progression[11, 13]. For example,
LSD1 was proposed as a therapeutic target, not only as a standalone approach but also in
combination with hormonal therapies[22]. Given the availability of LSD1 inhibitors in
preclinical and clinical stages, our results further support their exploration as a promising
additional therapy in breast cancer[14, 23].

355 In our analyses with TNBC cohorts, three histone methylation signals (H3K9me2, 356 H3K36me2, and H3K79me) emerge (and were validated) as independently associated 357 with TNBC, underscoring their potential role as subtype-specific epigenetic markers and therapeutic targets. This result aligns with published reports emphasizing the roles of 358 methylations on H3K36 and H3K79 in TNBC epigenetic regulation. For instance, distinct 359 patterns of H3K36me3 have been observed in TNBC cell lines, particularly in relation to 360 361 androgen receptor pathway activity[7]. Additionally, the chromatin state marked by H3K4me3 and H3K79me2 at loci such as AFAP1-AS1 has been identified as a hallmark 362 of TNBC, particularly in driving active transcription programs in these cells[7]. 363 364 Independent studies have confirmed that both NSD3, a histone methyltransferase responsible for H3K36me2, and DOT1L, which methylates H3K79, are highly expressed 365 in the MDA-MB-231 TNBC cell line[24, 25]. Inhibition or knockdown of these histone 366 writers leads to a reduction in H3K36me2 and H3K79me levels, respectively. This 367 reduction in histone modifications is associated with a significant decrease in cell 368 proliferation, migration, and invasion. Notably, in the context of TNBC, these effects are 369 370 often linked to the reversal of epithelial-to-mesenchymal transition (EMT), a key process that contributes to increased metastatic potential and the aggressive nature of cancer cells[26]. Here, our findings provide direct evidence from multiple cohorts of human tissue to support observations previously made in cell line studies and underscore the therapeutic potential of targeting histone writers like NSD3 and DOT1L in TNBC treatment strategies.

376 Mutations in histone H3 (such as H3K36M and H3K27M), so-called "oncohistones", 377 have been identified as significant contributors to tumorigenesis in certain cancers and thus was investigated in this study[27]. H3K36M is known to drive skeletal tumors like 378 379 chondroblastoma by dominantly inhibiting H3K36 methylation, leading to transcriptional 380 dysregulation and altered differentiation[28]. The H3K36M oncohistone primarily inhibits several H3K36-specific methyltransferases, leading to a reduction in all 381 methylation states of H3K36[29]. Similarly, the H3K27M mutation disrupts the 382 repressive H3K27me3 mark, resulting in widespread epigenetic reprogramming and 383 384 aberrant cellular proliferation or tumorigenesis[30]. In our study, neither H3K36M nor H3K27M mutations were detected in any of the BC tissue samples examined by 385 histological staining. These findings suggest that while H3 mutations play pivotal roles in 386 387 certain malignancies, their contribution to BC pathogenesis, particularly in the context of 388 our cohort, appears minimal. This highlights the need for further exploration into the unique histone modification patterns that define BC subtypes. 389

The most substantial finding presented here is that H3K9me2 deposited by G9a serves as an independent predictor, with its histological staining results effectively distinguishing TNBC from other breast cancer subtypes. Furthermore, inhibition of G9a drastically impairs the proliferation of breast cancer cell lines from various subtypes, including

luminal A, claudin-low TNBC and basal-like TNBC, underscoring its potential as a 394 therapeutic target across these subtypes. Comparing to H3K9me3 that is often linked to 395 396 the formation of heterochromatin defining stable and highly repressive chromatin states, H3K9me2 is less stable, associated with dynamic repression[7]. Its writer G9a has 397 398 broader substrate specificity, targeting both histone and non-histone proteins, such as p53, 399 CDYL, and ERa[31]. G9a is well-recognized as a coactivator in ER-positive breast 400 cancer, where its inhibition reactivates p53 and induces necroptosis, highlighting its dual 401 roles in tumor progression [32]. Mechanistically, G9a directly methylates $ER\alpha$, thereby 402 enhancing its transcriptional activity on genes that drive cell growth and survival[17]. 403 Experimental depletion of G9a in breast cancer cells and colorectal cancer stem cells has 404 been shown to suppress motility and disrupt ECM organization, underscoring its broader 405 role in cancer cell dynamics [33, 34]. Importantly, to our knowledge, our study is the first transcriptomic analysis profiling TNBC cells after G9a inhibitor treatment, uncovering 406 pathways that overlap but are not identical to RNAseq result from published G9a-407 408 knockdown experiments[35]. Our transcriptomic analysis of G9a-inhibited BC cells 409 supports previous findings by revealing G9a's critical role in maintaining ER activity in 410 ER-positive BC cells and promoting ECM signaling pathways in both ER-positive or negative BC cells. While ER signaling is specific to ER-positive cells, EMT pathway 411 regulation appears consistent across both ER-positive and ER-negative breast cancer cells, 412 highlighting G9a's broader influence on cellular processes irrespective of estrogen 413 receptor status[36, 37]. 414

Given G9a's involvement in estrogen receptor coactivation, it is considered a potential
therapeutic target for ER-positive breast cancer. However, its epigenetic role in ER-

negative breast cancer remains uncertain, given the absence of ER signaling in these 417 cancers. Notably, the IHC score of H3K9me2 in our cohorts is significantly higher in 418 419 higher-grade and later-stage tumors compared to healthy tissue, lower-grade, earlier-stage 420 or less aggressive subtypes like luminal A. This observation suggests that H3K9me2 may 421 play a more crucial role in the progression of more aggressive cancers or breast cancer 422 that doesn't have hormone receptors. Consistent to that, our findings show that G9a inhibition has a more profound inhibitory effect on cancer growth in basal-like TNBC > 423 424 claudin-low TNBC > luminal A BC, highlighting G9a's broader influence across different 425 BC subtypes via distinct pathways and mechanisms. Additionally, our results reinforce 426 earlier conclusions that G9a inhibitors induces apoptosis in breast cancer cell lines, with a more pronounced tumor volume reduction in MDA-MB-231 cells compared to MCF-7 427 cells[37]. Although cell proliferation was impaired, our transcriptomic profiling revealed 428 429 that G9a inhibition in TNBC cell lines uniquely induces the upregulation of oncogene 430 target genes and the downregulation of genes targeted by tumor suppressors such as SATB1 and TP53[38, 39]. This contrasts with prior studies that reported G9a inhibitors 431 432 effectively suppress tumor growth in preclinical models, though our findings diverge in 433 terms of the reactivation of silenced tumor suppressor genes [36, 40, 41]. This observation suggests that the heightened sensitivity of ER-negative breast cancer cells to G9a 434 435 inhibitors may be influenced by the epigenetic changes induced by treatment, rather than 436 reflecting a direct mechanistic basis.

This study, while providing valuable insights, has several limitations that warrant
consideration. The relatively small cohort size and lack of follow-up or survival data
impede a comprehensive understanding of the prognostic value of histone biomarkers.

Additionally, the scoring methodology, reliant on manual assessment, requires significant labor, experienced technicians, and carries the risk of manual error, emphasizing the need for automation through machine learning-driven imaging technology. Furthermore, the absence of in vivo validation limits the ability to confirm the therapeutic potential of G9a inhibitors, highlighting the need for preclinical studies and further investigation into its dualistic functions in breast cancer subtypes.

446 Conclusion

447 The immunohistochemical profiling and transcriptomic analyses presented in this study identify effective subtype-specific epigenetic targets in various BC subtypes, with a 448 449 particular focus on TNBC. The findings highlight G9a's multifaceted role in regulating both hormone-driven pathways and tumor suppressor mechanisms, demonstrating its 450 context-dependent influence. This research sheds light on the epigenetic complexity 451 underlying TNBC and provides valuable insights for developing targeted therapeutic 452 strategies, offering a promising avenue to improve outcomes for patients with this 453 454 challenging breast cancer subtype.

455 **Consent for publication**

456 All authors have read the manuscript and are consentaneous for publication.

457 **Funding**

This work was supported by National Natural Science Foundation of China (81672627;82071863).

460 Author contributions

XZ conceptualized the study design and the workflow, supervised all aspects of the 461 research, drafted figures and finalized the manuscript. ZH and SZ conducted experiments 462 (except those otherwise noted), processed samples, analyzed data, prepared illustrations, 463 and contributed to manuscript preparation. GS performed IHC staining for the discovery 464 cohort. YC supported the manuscript drafting and provided critical feedback. RC 465 466 developed the bioinformatics analysis pipeline. MJ, DY, and SZ offered supports on drafting experimental protocols and performing statistical analysis. YX assisted with 467 468 experiment design, supervised the experiments, and critically reviewed the manuscript.

- 469 Acknowledgments
- 470 We extend our gratitude to the commercial organizations and their patient contributors for
- 471 providing the tissue samples used in this study.
- 472 **Competing interests**
- 473 The authors have declared that no conflict of interest exists.

474 Availability of data and materials

- 475 Raw and processed files for RNA sequences (FASTQ format) supporting the findings of
- this study have been deposited in the National Center for Biotechnology Information
- 477 (NCBI) Gene Expression Omnibus (GEO) under accession number GSE283819.

479 **Reference**

- Bannister, A.J. and T. Kouzarides, *Regulation of chromatin by histone modifications*. Cell
 Res, 2011. **21**(3): p. 381-95.
- 482 2. Yang, Y., M. Zhang, and Y. Wang, *The roles of histone modifications in tumorigenesis and*483 *associated inhibitors in cancer therapy.* J Natl Cancer Cent, 2022. 2(4): p. 277-290.
- 3. Zhang, X., H. Wen, and X. Shi, *Lysine methylation: beyond histones*. Acta Biochim Biophys
 Sin (Shanghai), 2012. 44(1): p. 14-27.
- 486 4. Beňačka, R., et al., *Classic and New Markers in Diagnostics and Classification of Breast* 487 *Cancer.* Cancers (Basel), 2022. **14**(21).
- 4885.Eccles, S.A., et al., Critical research gaps and translational priorities for the successful489prevention and treatment of breast cancer. Breast Cancer Res, 2013. **15**(5): p. R92.
- 490 6. Zhuang, J., et al., *Perspectives on the Role of Histone Modification in Breast Cancer*491 *Progression and the Advanced Technological Tools to Study Epigenetic Determinants of*492 *Metastasis.* Front Genet, 2020. **11**: p. 603552.
- 4937.Xi, Y., et al., Histone modification profiling in breast cancer cell lines highlights494commonalities and differences among subtypes. BMC Genomics, 2018. **19**(1): p. 150.
- 495 8. Borkiewicz, L., *Histone 3 Lysine 27 Trimethylation Signature in Breast Cancer.* Int J Mol Sci,
 496 2021. 22(23).
- 497 9. Li, W., et al., *Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the*498 Way. Front Cell Dev Biol, 2021. 9: p. 736935.
- 49910.Cheng, Y., et al., Targeting epigenetic regulators for cancer therapy: mechanisms and500advances in clinical trials. Signal Transduct Target Ther, 2019. **4**: p. 62.
- 50111.Marzochi, L.L., et al., Use of histone methyltransferase inhibitors in cancer treatment: A502systematic review. Eur J Pharmacol, 2023. 944: p. 175590.
- 50312.White, J., et al., Histone lysine acetyltransferase inhibitors: an emerging class of drugs for504cancer therapy. Trends Pharmacol Sci, 2024. **45**(3): p. 243-254.
- 50513.Liao, Q., et al., Novel insights into histone lysine methyltransferases in cancer therapy:506From epigenetic regulation to selective drugs. J Pharm Anal, 2023. 13(2): p. 127-141.
- 50714.Gold, S. and A. Shilatifard, Epigenetic therapies targeting histone lysine methylation:508complex mechanisms and clinical challenges. J Clin Invest, 2024. 134(20).
- 50915.Feng, J. and X. Meng, Histone modification and histone modification-targeted anti-510cancer drugs in breast cancer: Fundamentals and beyond. Front Pharmacol, 2022. 13: p.511946811.
- 512 16. Zhang, X., et al., *Regulation of estrogen receptor α by histone methyltransferase SMYD2-*513 *mediated protein methylation.* Proc Natl Acad Sci U S A, 2013. **110**(43): p. 17284-9.
- 51417.Zhang, X., et al., G9a-mediated methylation of ERα links the PHF20/MOF histone515acetyltransferase complex to hormonal gene expression. Nat Commun, 2016. **7**: p. 10810.
- 51618.Chen, Y., et al., MicroRNA-133b is regulated by TAp63 while no gene mutation is present517in colorectal cancer. Oncol Rep, 2017. **37**(3): p. 1646-1652.
- 51819.Fang, Y., et al., Protein expression of ZEB2 in renal cell carcinoma and its prognostic519significance in patient survival. PLoS One, 2013. 8(5): p. e62558.
- Vini, R., et al., 27-Hydroxycholesterol represses G9a expression via oestrogen receptor
 alpha in breast cancer. J Cell Mol Med, 2023. 27(18): p. 2744-2755.
- 522 21. Garcia-Martinez, L., et al., *Epigenetic mechanisms in breast cancer therapy and* 523 *resistance*. Nat Commun, 2021. **12**(1): p. 1786.

524 525	22.	Prasanna, T., et al., A Phase 1 Proof of Concept Study Evaluating the Addition of an LSD1 Inhibitor to Nab-Paclitaxel in Advanced or Metastatic Breast Cancer (EPI-PRIMED). Front
526		Oncol, 2022. 12 : p. 862427.
527	23.	Noce, B., et al., LSD1 inhibitors for cancer treatment: Focus on multi-target agents and
528		compounds in clinical trials. Front Pharmacol, 2023. 14: p. 1120911.
529	24.	Byun, W.S., et al., Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A
530		Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer. Mol Ther
531		Oncolytics, 2019. 15 : p. 140-152.
532	25.	Jeong, G.Y., et al., NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to
533		Drive Breast Tumor Initiation and Metastatic Progression. Cancer Res, 2021. 81(1): p. 77-
534		90.
535	26.	Grasset, E.M., et al., Triple-negative breast cancer metastasis involves complex epithelial-
536		mesenchymal transition dynamics and requires vimentin. Sci Transl Med, 2022. 14(656):
537		p. eabn7571.
538	27.	Sahu, V. and C. Lu, Oncohistones: Hijacking the histone code. Annu Rev Cancer Biol, 2022.
539		6 : p. 293-312.
540	28.	Fang, D., et al., The histone H3.3K36M mutation reprograms the epigenome of
541		chondroblastomas. Science, 2016. 352 (6291): p. 1344-8.
542	29.	Rajagopalan, K.N., et al., Depletion of H3K36me2 recapitulates epigenomic and
543		phenotypic changes induced by the H3.3K36M oncohistone mutation. Proc Natl Acad Sci
544		U S A, 2021. 118 (9).
545	30.	Harutyunyan, A.S., et al., H3K27M induces defective chromatin spread of PRC2-mediated
546		repressive H3K27me2/me3 and is essential for glioma tumorigenesis. Nat Commun,
547		2019. 10 (1): p. 1262.
548	31.	Zhang, X., Y. Huang, and X. Shi, Emerging roles of lysine methylation on non-histone
549		proteins. Cell Mol Life Sci, 2015. 72 (22): p. 4257-72.
550	32.	Mabe, N.W., et al., G9a Promotes Breast Cancer Recurrence through Repression of a Pro-
551		<i>inflammatory Program.</i> Cell Rep, 2020. 33 (5): p. 108341.
552	33.	Jin, Y., et al., G9a Knockdown Suppresses Cancer Aggressiveness by Facilitating Smad
553		Protein Phosphorylation through Increasing BMP5 Expression in Luminal A Type Breast
554		<i>Cancer.</i> Int J Mol Sci, 2022. 23 (2).
555	34.	Bergin, C.J., et al., G9a controls pluripotent-like identity and tumor-initiating function in
556		<i>human colorectal cancer.</i> Oncogene, 2021. 40 (6): p. 1191-1202.
557	35.	Kim, K., et al., RNA-seq based transcriptome analysis of EHMT2 functions in breast cancer.
558		Biochem Biophys Res Commun, 2020. 524 (3): p. 672-676.
559	36.	Liu, X.R., et al., UNC0638, a G9a inhibitor, suppresses epithelial-mesenchymal
560		transition-mediated cellular migration and invasion in triple negative breast cancer. Mol
561		Med Rep, 2018. 17 (2): p. 2239-2244.
562	37.	Dong, C., et al., G9a interacts with Snail and is critical for Snail-mediated E-cadherin
563		repression in human breast cancer. J Clin Invest, 2012. 122 (4): p. 1469-86.
564	38.	Han, H.J., et al., SATB1 reprogrammes gene expression to promote breast tumour growth
565		and metastasis. Nature, 2008. 452 (7184): p. 187-93.
566	39.	Silwal-Pandit, L., et al., TP53 mutation spectrum in breast cancer is subtype specific and
567		has distinct prognostic relevance. Clin Cancer Res, 2014. 20 (13): p. 3569-80.
568	40.	Zhang, Q., et al., Discovery of novel G9a/GLP covalent inhibitors for the treatment of
569		triple-negative breast cancer. Eur J Med Chem, 2023. 261 : p. 115841.

570 41. Casciello, F., et al., *G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome.* Theranostics, 2020.
572 **10**(10): p. 4515-4529.





A					
Histone Mod.	Transcriptional Reg.	Role in BC	High-IHC %		
H3K4me2	Activation	Promotes growth	71.43		
H3K9me2	Repression	Represses growth	40.82		
H3K9ac	Activation	Promotes growth	19.39		
H3K18ac	Activation	Promotes growth	70.41		
H3K27me3	Repression	Represses growth	25.00		
H3K27ac	Activation	Promotes growth	50.00		
H3K36me2	Activation	Represses growth	50.51		
H3K79me1/2/3	Activation	Promotes growth	31.12		
H4K12ac	Activation	Promotes growth	37.24		
H4K16ac	Activation	Represses growth	32.65		
H4K20me3	Repression	Represses growth	61.73		
H4R3me2	Dual Roles	Promotes growth	33.16		
Methyltransferase	Histone Target	Role in BC	High-IHC %		
DNMT1	DNA	Oncogene	42.86		
G9a/EHMT2	H3K9me1/2	Oncogene	12.62		
EZH2	H3K27me3	Oncogene	66.33		
SMYD2/KMT3C	H3K36me1/2	Oncogene	58.67		
NSD1/KMT3B	H3K36me2/3	Dual roles	56.12		
Demethylase	Histone Target	Role in BC	High-IHC %		
LSD1	H3K4/9me1/2	Oncogene	69.39		
KDM3A/JHDM2A	H3K9me1/2	Oncogene	12.76		
Histone Mutation	Impact	Role in Cancer			
H3K27M	H3K27me3 loss	Promotes growth			
H3K36M	H3K27me1/2/3 loss	Promotes growth			



С

H3K18ac



H3K36me2

H3K79me







26

20 µm

Α

Row Row

min	max	Grade			Tumor Stage T and N					Clinical Stage			
		2	2/3	3	T2	Т3	T4	N0	N1	N2	П	III	
[12.0	6.3	18.2	6.4	8.6	18.4	10.4	17.4	12.5	7.6	16.7	H3K9me2
		47.5	6.3	36.4	39.4	43.1	42.1	41.8	45.7	43.8	39.4	46.7	DNMT1
		38.6	18.8	40.9	37.2	27.6	42.1	41.8	32.6	12.5	37.1	33.3	H4K12ac
		75.9	62.5	45.5	73.4	60.3	78.9	76.1	71.7	31.3	75.0	61.7	H3K4me2
		67.1	37.5	40.9	62.8	56.9	60.5	64.9	63.0	31.3	65.9	50.0	H4K20me3
		35.4	25.0	4.5	28.7	32.8	23.7	34.3	30.4	6.3	31.8	25.0	H3K79me
		71.5	68.8	63.6	69.1	79.3	60.5	76.9	67.4	25.0	77.3	53.3	H3K18ac
		52.5	25.0	50.0	45.7	63.8	39.5	55.2	45.7	18.8	56.1	36.7	H3K27ac
		70.9	37.5	54.5	63.8	74.1	55.3	69.4	69.6	31.3	71.2	53.3	EZH2
		60.1	31.3	45.5	52.1	58.6	55.3	61.9	47.8	31.3	56.1	53.3	NSD1
		30.4	75.0	22.7	18.1	27.6	78.9	26.9	56.5	18.8	19.7	65.0	H4R3me2
		58.9	68.8	50.0	44.7	55.2	92.1	59.7	58.7	50.0	50.0	75.0	SMYD2
		41.1	75.0	13.6	31.9	43.1	55.3	47.8	32.6	6.3	39.4	40.0	G9a
		13.9	12.5	4.5	10.6	8.6	10.5	14.9	8.7	6.3	11.4	10.0	КДМЗА

В









TFF1







Α

Claudin-low TNBC (24) Basal-like TNBC Luminal A Upregulated DEG Downregulated DEG Upregulated GSEA Upregulated KEGG Upregulated GO



